Skip to main content
Premium Trial:

Request an Annual Quote

Cellectricon, AstraZeneca Extend Collaboration

NEW YORK (GenomeWeb News) – Cellectricon today said that it has signed a new agreement with AstraZeneca, under which the drug giant will use two of the firm’s DynaFlow HT platforms for ion channel screening.
 
The partners initially started collaborating in 2006 on developing an ion channel screening platform. The results of the collaboration demonstrated the performance capabilities of the cell-based microfluidic screening platform, said Gothenburg, Sweden-based Cellectricon.
 
The company said that the DynaFlow HT System will be commercially launched in 2009.